Cancer Research Cell Death Mechanisms and Cancer Therapy Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mohammed, S. I.
Right arrow Articles by Knapp, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mohammed, S. I.
Right arrow Articles by Knapp, D. W.
[Cancer Research 62, 356-358, January 15, 2002]
© 2002 American Association for Cancer Research

Advances in Brief

Effects of the Cyclooxygenase Inhibitor, Piroxicam, on Tumor Response, Apoptosis, and Angiogenesis in a Canine Model of Human Invasive Urinary Bladder Cancer1

Sulma I. Mohammed, Peter F. Bennett, Bruce A. Craig, Nita W. Glickman, Anthony J. Mutsaers, Paul W. Snyder, William R. Widmer, Amalia E. DeGortari, Patty L. Bonney and Deborah W. Knapp2

Departments of Veterinary Clinical Sciences [S. I. M., P. F. B., A. J. M., W. R. W., A. E. D., P. L. B., D. W. K.], Statistics [B. A. C.], Research Programs [N. W. G.], and Veterinary Pathobiology [P. W. S.], Purdue University, West Lafayette, Indiana 47907

The mechanisms by which cyclooxygenase inhibitors exert antitumor effects are not completely defined but are postulated to involve antiangiogenic effects and induction of apoptosis. In this study, we determined the effects of the cox inhibitor, piroxicam, on tumor response, apoptotic index, proliferative index, cyclooxygenase-2 expression, prostaglandin E2 concentration, tumor microvessel density, and urine basic fibroblast growth factor and vascular endothelial growth factor concentrations in pet dogs with naturally occurring invasive transitional cell carcinoma of the urinary bladder. Piroxicam caused reduction in tumor volume in 12 of 18 dogs, and this was strongly associated with induction of apoptosis (Fisher’s exact test P < 0.015) and reduction in urine basic fibroblast growth factor concentration.




This article has been cited by other articles:


Home page
 Vet PatholHome page
S. J. Baek, M. F. McEntee, and A. M. Legendre
REVIEW PAPER: Cancer Chemopreventive Compounds and Canine Cancer
Vet. Pathol., July 1, 2009; 46(4): 576 - 588.
[Abstract] [Full Text] [PDF]

Home page
 Vet PatholHome page
D. H. Thamm, E. J. Ehrhart III, J. B. Charles, and Y. A. Elce
Cyclooxygenase-2 Expression in Equine Tumors
Vet. Pathol., November 1, 2008; 45(6): 825 - 828.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. Dhawan, A. B. Jeffreys, R. Zheng, J. C. Stewart, and D. W. Knapp
Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells
Mol. Cancer Ther., April 1, 2008; 7(4): 897 - 904.
[Abstract] [Full Text] [PDF]

Home page
 Vet Rec.Home page
S. Boonsoda and P. Wanikiat
Possible role of cyclooxygenase-2 inhibitors as anticancer agents
Vet Rec., February 2, 2008; 162(5): 159 - 161.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
F. Finetti, R. Solito, L. Morbidelli, A. Giachetti, M. Ziche, and S. Donnini
Prostaglandin E2 Regulates Angiogenesis via Activation of Fibroblast Growth Factor Receptor-1
J. Biol. Chem., January 25, 2008; 283(4): 2139 - 2146.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. P. Spugnini, I. Cardillo, A. Verdina, S. Crispi, S. Saviozzi, R. Calogero, A. Nebbioso, L. Altucci, G. Cortese, R. Galati, et al.
Piroxicam and Cisplatin in a mouse model of peritoneal mesothelioma.
Clin. Cancer Res., October 15, 2006; 12(20): 6133 - 6143.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. Fortuny, M. Kogevinas, M. Garcia-Closas, F. X. Real, A. Tardon, R. Garcia-Closas, C. Serra, A. Carrato, J. Lloreta, N. Rothman, et al.
Use of Analgesics and Nonsteroidal Anti-inflammatory Drugs, Genetic Predisposition, and Bladder Cancer Risk in Spain.
Cancer Epidemiol. Biomarkers Prev., September 1, 2006; 15(9): 1696 - 1702.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. I. Mohammed, D. Dhawan, S. Abraham, P. W. Snyder, D. J. Waters, B. A. Craig, M. Lu, L. Wu, R. Zheng, J. Stewart, et al.
Cyclooxygenase inhibitors in urinary bladder cancer: in vitro and in vivo effects.
Mol. Cancer Ther., February 1, 2006; 5(2): 329 - 336.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
E. M. Sievers, R. D. Bart, L. M. Backhus, Y. Lin, M. Starnes, R. Castanos, V. A. Starnes, and Ross. M. Bremner
Evaluation of cyclooxygenase-2 inhibition in an orthotopic murine model of lung cancer for dose-dependent effect
J. Thorac. Cardiovasc. Surg., June 1, 2005; 129(6): 1242 - 1249.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. D. Klein, C. S. Van Pelt, A. L. Sabichi, J. dela Cerda, S. M. Fischer, G. Furstenberger, and K. Muller-Decker
Transitional Cell Hyperplasia and Carcinomas in Urinary Bladders of Transgenic Mice with Keratin 5 Promoter-Driven Cyclooxygenase-2 Overexpression
Cancer Res., March 1, 2005; 65(5): 1808 - 1813.
[Abstract] [Full Text] [PDF]

Home page
 Journal of the American Animal Hospital AssociationHome page
V. J. Poirier, L. J. Forrest, W. M. Adams, and D. M. Vail
Piroxicam, Mitoxantrone, and Coarse Fraction Radiotherapy for the Treatment of Transitional Cell Carcinoma of the Bladder in 10 Dogs: A Pilot Study
J. Am. Anim. Hosp. Assoc., March 1, 2004; 40(2): 131 - 136.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. L. Lovering, J. P. Ride, C. M. Bunce, J. C. Desmond, S. M. Cummings, and S. A. White
Crystal Structures of Prostaglandin D2 11-Ketoreductase (AKR1C3) in Complex with the Nonsteroidal Anti-Inflammatory Drugs Flufenamic Acid and Indomethacin
Cancer Res., March 1, 2004; 64(5): 1802 - 1810.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
J. E. Castelao, R. D. Bart III, C. A. DiPerna, E. M. Sievers, and R. M. Bremner
Lung cancer and cyclooxygenase-2
Ann. Thorac. Surg., October 1, 2003; 76(4): 1327 - 1335.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
H. Choy and L. Milas
Enhancing Radiotherapy With Cyclooxygenase-2 Enzyme Inhibitors: A Rational Advance?
J Natl Cancer Inst, October 1, 2003; 95(19): 1440 - 1452.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. Salcedo, X. Zhang, H. A. Young, N. Michael, K. Wasserman, W.-H. Ma, M. Martins-Green, W. J. Murphy, and J. J. Oppenheim
Angiogenic effects of prostaglandin E2 are mediated by up-regulation of CXCR4 on human microvascular endothelial cells
Blood, September 15, 2003; 102(6): 1966 - 1977.
[Abstract] [Full Text] [PDF]

Home page
 Vet PatholHome page
S. L. Beam, K. M. Rassnick, A. S. Moore, and S. P. McDonough
An Immunohistochemical Study of Cyclooxygenase-2 Expression in Various Feline Neoplasms
Vet. Pathol., September 1, 2003; 40(5): 496 - 500.
[Abstract] [Full Text] [PDF]

Home page
 Vet PatholHome page
G. Borzacchiello, V. Ambrosio, P. Galati, A. Perillo, and F. Roperto
Cyclooxygenase-1 and -2 Expression in Urothelial Carcinomas of the Urinary Bladder in Cows
Vet. Pathol., July 1, 2003; 40(4): 455 - 459.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. J. Henry, D. L. McCaw, S. E. Turnquist, J. W. Tyler, L. Bravo, S. Sheafor, R. C. Straw, W. S. Dernell, B. R. Madewell, L. Jorgensen, et al.
Clinical Evaluation of Mitoxantrone and Piroxicam in a Canine Model of Human Invasive Urinary Bladder Carcinoma
Clin. Cancer Res., February 1, 2003; 9(2): 906 - 911.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.